Middle Meningeal Artery Embolisation in Chronic Subdural Hematoma
NCT: NCT07751887 · ACTIVE_NOT_RECRUITING
Brief Summary
This international multicenter study evaluates the efficacy and safety of middle meningeal artery embolization (MMAE) using PVA particles or liquid embolic agents as a perioperative treatment to prevent the recurrence of chronic subdural hematoma (cSDH). All participating patients across centers in the Czech Republic and Slovakia will receive the minimally invasive MMAE procedure within 7 days prior to or after surgical evacuation, with the primary goal of assessing hematoma recurrence rates and procedure-related complications over a 90-day follow-up period.
Frequently Asked Questions
What is Middle Meningeal Artery Embolisation in Chronic Subdural Hematoma?
Middle Meningeal Artery Embolisation in Chronic Subdural Hematoma is a clinical trial registered under NCT07751887. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT07751887?
The current status of NCT07751887 (Middle Meningeal Artery Embolisation in Chronic Subdural Hematoma) is: ACTIVE_NOT_RECRUITING.
When did Middle Meningeal Artery Embolisation in Chronic Subdural Hematoma start?
Middle Meningeal Artery Embolisation in Chronic Subdural Hematoma started on 2026-06-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.